Valvular heart disease and fibrotic reactions may be related to ergot dopamine agonists, but non‐ergot agonists may also not be spared
この論文をさがす
説明
<jats:title>Abstract</jats:title><jats:p>Companion letters have been published in this issue of <jats:italic>Movement</jats:italic> Disorders: <jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.1002/mds.20329">Horowski et al., pp 1523–1524</jats:ext-link>, and <jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="doi" xlink:href="10.1002/mds.20328">Rascol et al., pp 1524–1525</jats:ext-link>.</jats:p>
収録刊行物
-
- Movement Disorders
-
Movement Disorders 19 (12), 1522-1523, 2004-10-27
Wiley